These results suggest that interference with eIF5B expression can enhance the killing capability of PBMCs on prostate cancer cells, while PD-L1 overexpression based on the interference of eIF5B expression may weaken such enhancement. The gene discussed is CD274; the disease is Familial prostate cancer.